AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS B SPARKMAN | — |
| SUSAN VAN METER | — |
Medicare/Medicaid MMM
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, Telehealth Extension and Evaluation Act S. 3593, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS B SPARKMAN | — |
| SUSAN VAN METER | — |
Budget/Appropriations BUD
Reimbursement and coverage issues for and related to clinical laboratory services, including implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS B SPARKMAN | — |
| SUSAN VAN METER | — |
Health Issues HCR
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS B SPARKMAN | — |
| SUSAN VAN METER | — |
Disaster Planning/Emergencies DIS
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS B SPARKMAN | — |
| SUSAN VAN METER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.